News

Filter

1 to 9 of 18 results

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

UK health system spends most on AbbVie's Humira overall, according to HSCIC data on prescribing habits

12-11-2014

The Health & Social Care Information Centre has published its report on the prescribing habits of the…

HumiraLucentisMarkets & MarketingNational Health ServicePharmaceuticalResearchUKUnited Kingdom

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

French competition authority investigating Roche and Novartis over Lucentis marketing

10-04-2014

Following similar recent action by the equivalent Italian body, the French competition authority is launching…

AvastinBevacizumabFranceItalyLegalLucentisMarkets & MarketingMedicineNorthern EuropeNovartisOphthalmicsPharmaceuticalPharmacologyRocheUSD

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

Strong uptake of Regeneron/Bayer wet AMD drug Eylea in USA, but Avastin still leads

11-07-2013

The majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal…

AllerganAvastinBayerBiotechnologyEyleaFovistaLucentisMarkets & MarketingNorth AmericaOphthalmicsOphthotechPharmaceuticalRegeneronRoche

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

pSivida and Alimera's Iluvien debuts in Germany; New data on Novartis' Lucentis

08-05-2013

USA-based pSivida Corp (Nasdaq: PSDV), a leader in developing sustained release, drug delivery products…

Alimera SciencesIluvienLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalpSividaResearch

1 to 9 of 18 results

COMPANY SPOTLIGHT

Menarini

Back to top